INC280 (capmatinib) for Carcinoma, Non-Small-Cell Lung
This study is evaluating whether a drug that blocks a protein called c-MET can help treat lung cancer.
See full descriptionAbout the trial for Carcinoma, Non-Small-Cell Lung
Treatment Groups
This trial involves 7 different treatments. INC280 (capmatinib) is the primary treatment being studied. Participants will be divided into 7 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received newly diagnosed for Carcinoma, Non-Small-Cell Lung or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether INC280 (capmatinib) will improve 9 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of 6 weeks.
Patient Q & A Section
What causes carcinoma, non-small-cell lung?
There is no clear association between smoking or type of drinking and carcinoma, non-small-cell lung. It remains unclear why lung carcinoma is more common at sites of lower altitude.
What is carcinoma, non-small-cell lung?
The lung forms about 22,000 deaths per year in the United Kingdom. In the United States, [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) is the fourth leading cause of cancer-related death, after breast, colorectal and lung cancers, and accounts for about 21% of cancer deaths. About 4% of NSCLC is caused by tobacco smoke. Of the remaining 86%, about half are caused by viral infections, particularly the common cold, and 35% are now associated with viral infections. Some viruses that cause lung cancer, especially in childhood, are human papillomavirus, Kaposi sarcoma-associated herpesvirus, human T-cell leukemia virus, and rhinovirus.
How many people get carcinoma, non-small-cell lung a year in the United States?
The numbers of new cases of carcinoma, non-small-cell lung and lung adenocarcinoma vary not only geographically in the United States but are also high in whites but not blacks.
What are the signs of carcinoma, non-small-cell lung?
[The main signs of lung carcinoma are an increasing degree of dyspnoea, cough and hemoptysis, and coughing up blood. A CT scan is required to make the final diagnosis of lung carcinoma. Patients in clinical trials must inform their doctors of the study they are taking part in. If they are already on treatment, the clinicians must provide a comprehensive documentation of all the drugs the patients are taking. With this information and a patient history, the doctors decide which tests may be useful to help identify the cancer. With a CT scan the doctors can decide on an appropriate treatment course and monitor the patient during the treatment.
Can carcinoma, non-small-cell lung be cured?
Lung cancer has no cure. The prognosis, in general, depends on a large number of factors, including the type of cancer, size and stage, the patient's history, and the presence of comorbidities in the case of a malignant process. The response to surgical resection varies at the metastatic stage between cases of adenocarcinoma and squamous cell carcinoma on the one hand, and between localized diseases (tumours localized to the lung without nodal metastases) and metastatic non-small cell lung cancer (NSCLC - metastatic disease to lung without nodal metastases) on the other. The survival of the patients varies depending on the stage and the type of cancer.
What are common treatments for carcinoma, non-small-cell lung?
[Patients with NSCLC or squamous cell carcinoma have an overall five-year survival rate of around 30%; patients with adenocarcinoma have an overall five-year survival of around 50%.
What are the chances of developing carcinoma, non-small-cell lung?
[About 18% of the cases found have non-small-cell lung carcinoma]. Even if the patient has never had smoking, the chances of developed carcinoma, non-small-cell lung are higher.
Does inc280 (capmatinib) improve quality of life for those with carcinoma, non-small-cell lung?
These data suggest that inc280 is efficacious in patients with carcinoma, non-small-cell lung and is generally well-tolerated. In a recent study, findings highlights the impact on HRQoL on many patients with lung cancer and the importance of assessing treatment benefit in this population.
What are the common side effects of inc280 (capmatinib)?
Inc280 is effective in suppressing the growth of NSCLC cells and suppressing C/EBP homologous protein translocation. The treatment was well-tolerated and no serious toxicity was observed.
How serious can carcinoma, non-small-cell lung be?
The risk of being hospitalized or dying after a non- small cell carcinoma, non-small cell lung is extremely low. If patients are informed of the low mortality it will greatly help their decision making but also the patients, family and friends.
What are the latest developments in inc280 (capmatinib) for therapeutic use?
Results from a recent paper of the current study demonstrate that the therapeutic response to capmatinib is not limited to tumors with epidermal growth factor receptor mutations.
Has inc280 (capmatinib) proven to be more effective than a placebo?
Inc280 treatment was shown to be more effective than a placebo as measured based on a single-blind protocol in patients with mCRPC and previously treated with at least two or more chemotherapies. Inc280 continued to show a meaningful antiproliferative effect in the majority of patients.